The cumulative incidence of gemcitabine-induced thrombotic microangiopathy [1]

Acta Oncologica

Volumn 46, Issue 4, 2007, Pages 545-546

  Arnadottir, Margret ^a   Benediktsson, Thorir ^a   Hrafnkelsson, Jon ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; ANEMIA; CASE REPORT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LETTER; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; ICELAND; INCIDENCE; MIDDLE AGED; NEOPLASMS; PERIPHERAL VASCULAR DISEASES; THROMBOCYTOPENIA;

EID: 34248594273     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600975268     Document Type: Letter

References (4)

1. Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: Kaplan BS, Trompeter RS, Moake JL, editors. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker; 1992. p. 271-85.
2. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, et al. Review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32.
3. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664-70.
4. Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: Report of four cases from a single institution. Ann Hematol 2005;84:110-4.